Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma

Primary Liver Cancers Clinical Trial

Official title: Assessment and Impact of Portal Hypertension Before and During Liver Resection in Patients With Hepatocellular Carcinoma

Status Active, not recruiting

Clinical Trial Summary

According to the BCLC guidelines, surgical resection of hepatocellular carcinoma complicating cirrhosis is restricted to patients with preserved liver function, single nodule without vascular invasion and with hepatic venous gradient below 10 mmHg.

However, other guideline treatment, especially from eastern countries demonstrated that surgical resection is safe and feasible and provides better survival than the treatment recommended by the BCLC system for patients with similar stage.

The primary goal of this study is to assess the impact of HVPG on short and long-term outcomes in HCC patients who undergo liver resection.

Clinical Trial Description

Patients with HCC and candidates for hepatectomy are classified into two groups according to the presence of portal hypertension. Short- and long-term outcomes will be compared. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hypertension
• Hypertension, Portal
• Liver Neoplasms
• Primary Liver Cancers

• NCT number: NCT02145013
• Study type: Observational
• Source: Henri Mondor University Hospital
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 2013
• Completion date: May 30, 2018